Vice versa, T1-IFN immunotherapy as treatment for other diseases is known to cause symptoms similar to those observed in AID, such as development of psoriatic lesions in MS or hepatitis C-infected patients (239, 240). This evidence concerns the gene IFNA1 and hepatitis C virus infection.